Head-to-head · WeighScore
Spry vs TD Tele-Doc Weight Loss
The verdict
TD Tele-Doc Weight Loss takes it — 61.8/100 to 56.8/100.
TD Tele-Doc Weight Loss grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. TD Tele-Doc Weight Loss is a 100% virtual telehealth practice serving Virginia and Maryland that prescribes FDA-approved brand GLP-1 medications (Wegovy, Zepbound, Ozempic, Mounjaro) and compounded…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Spry | TD Tele-Doc Weight Loss |
|---|---|---|
| WeighScore | 56.8/100 | 61.8/100 |
| Grade | C | C |
| Scorecard rank | #408 | #286 |
| Semaglutide | $199/mo (starting dose, compounded) | Not disclosed |
| Tirzepatide | $299/mo (starting dose, compounded) | Not disclosed |
| Coverage | Coverage not published | 2 states |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #408 · C
Strengths
- Three named co-founders disclosed (Gabriel Mullins, Sara Yoder, Tyler Bowman) — better-than-average transparency
- Pricing shown on the homepage ($199 semaglutide / $299 tirzepatide / $249–$299 peptides) — no full sign-up wall
- Broader range (2 GLP-1s plus 3 anti-aging peptides) appeals to longevity buyers
- No contracts or commitment required
- LegitScript Certified with a public verification link
Where it loses points
- Displays an "FDA Approved" badge though compounded GLP-1s are not FDA-approved finished drugs — potentially misleading
- Intake reviewed by a nurse practitioner, not an MD
- States served not disclosed publicly
- Pharmacy partner not named, and 503A vs 503B designation not specified
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Graded #286 · C
Strengths
- Brand Wegovy/Zepbound AND compounded sema available; prescribing based on medical history and coverage
- 100% virtual — weekly appointments with board-certified MDs from home; no travel required
- Remote Patient Monitoring Starter Box: biometric scale + blood pressure cuff sync to care team in real time
- In-network with most commercial insurance plans; may cover visits and monitoring equipment
- Physician-led by Dr. Peter Wilbanks MD (30-yr OB/GYN, VCU) and Dr. Michael Perini MD (ABIM board-certified)
Where it loses points
- No public cash pricing; cost entirely depends on insurance coverage — not viable for uninsured patients
- Telehealth available only in Virginia and Maryland; no national reach confirmed
- No Medicare or Medicaid accepted; limited to commercial insurance plans only
- No LegitScript certification found; compounded availability and specific pricing undisclosed on site
- Tirzepatide (Zepbound/Mounjaro) availability less prominent in MD pages; semaglutide is primary focus
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.